States are increasingly well-informed of the potential restrictive impacts of federal trade policy and treaties on state prescription drug purchasing practices, including preferred drug lists and importation. The pharmaceutical industry has moved aggressively to put its stamp on international trade agreements that would encourage federal preemption of state innovation and also delay the introduction of less expensive generic drugs. Through the NLARx Working Group on Prescription Drugs and Trade, state legislators, Medicaid experts, and representatives of state attorneys general have directly engaged with the U.S. Trade Representative through meetings and exchanges of correspondence. NLARx has made educational presentations on trade policy related to prescription drugs to state legislative committees, members of Congress, and National Conference of State Legislatures committees. NLARx has also supported establishing institutional mechanisms within the states to provide ongoing oversight of trade policy related to medicines. States including California, Maine, Vermont and Washington have created such advisory commissions or legislative oversight committees.

Researching this Issue

Model laws and resolutions, testimony supporting these initiatives, and background information and research materials on trade and pharmaceutical policy, including reports and news articles, are posted here. Other relevant materials may be found on the related issue page on Importation policy. The Pharma Watch page details drug industry tactics including trade-related activities. See also the Related Links below to connect to other organizations and materials relevant to this issue, particularly the Forum on Democracy & Trade, which has very detailed information on pharmaceutical industry-related trade policy and trade issues generally, including up to date information on the status of various trade negotiations and treaties. The Forum works closely with NLARx and jointly coordinates the Working Group on Prescription Drugs and Trade.

Model Legislation
Jan 24, 2011
January 21, 2011 Legislators Endorse Resolution Opposing Pharmaceutical Chapter in TPP and Other Trade Agreements | >>more
Mar 01, 2006
California Trade Resolution on Pharmaceutical Policy | >>more
Jun 08, 2005
Model Trade Resolution | >>more
May 18, 2011
NLARx signed onto comments regarding potential pharmaceutical pricing provisions in the TransPacific Trade Agreement | >>more
Sep 16, 2010
NLARx Signs on to Letter to USTR on Pharmaceutical Pricing Chapter in TPP Negotiations | >>more
Feb 16, 2010
NLARx Notice of Intent to Testify and Summary of Testimony Concerning the 2010 Special 301 Review | >>more
>> view all Testimony
Related News
Sep 15, 2011
Center for Policy Analysis on Trade and Health
Medicine and Public Health Groups Oppose U.S. Trans-Pacific Partnership Threats to Tobacco Control, Affordable Medicines AMA, AAP, ACPM, AMSA, CPATH Call for New Direction in Trade Talks | >>more
Sep 15, 2011
Intellectual Property Watch
USTR White Paper On Trade In Medicines Raises Questions | >>more
Sep 15, 2011
November Deadline for Obama’s First Trade Deal Falls Away as Controversies Roil Chicago Trans-Pacific Trade Talks | >>more
>> view all News
Jun 07, 2011
The Korea-US Free Trade Agreement Threatens Federal "340"B Discounts for Medicines for Low Income Americans | >>more
Jun 07, 2011
ISSUE BRIEF: State and Consumer Opposition to Trade Agreement Restrictions on Pharmaceutical Reimbursement and Pricing Programs | >>more
Nov 10, 2009
A New Trade Agreement on Pharmaceutical Pricing and Reimbursement? | >>more
>> view all Reports
Search The Site:
Join NLARx Today
arrow Membership Details
arrow Member News Page